Economic impact of vitamin D treatment on chronic kidney disease patients;Impacto económico del tratamiento con vitamina D en pacientes con enfermedad renal crónica

Nefrologia

Volumn 31, Issue 5, 2011, Pages 528-536

  Ramos, R ^a   Alcazar R ^b   Otero, A ^c   de Francisco, A L M ^d   del Pino, M D ^e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c Hospital Universitario de Ourense   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL TORRECÁRDENAS   (Spain)

Author keywords

Chronic kidney disease; Cost effectiveness; Vitamin D

Indexed keywords

CALCITRIOL RECEPTOR; VITAMIN D;

ANIMAL; ARTICLE; CARDIOVASCULAR DISEASE; CHEMISTRY; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COST CONTROL; DRUG POTENTIATION; ECONOMICS; HUMAN; INFLAMMATION; KIDNEY DISEASE; META ANALYSIS (TOPIC); METABOLISM; PARACRINE SIGNALING; PRACTICE GUIDELINE; RAT; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COST SAVINGS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INFLAMMATION; KIDNEY DISEASES; META-ANALYSIS AS TOPIC; PARACRINE COMMUNICATION; PRACTICE GUIDELINES AS TOPIC; RATS; RECEPTORS, CALCITRIOL; RENAL OSTEODYSTROPHY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 82755162104     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Aug.11012     Document Type: Article

References (51)

1. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005;45:1026-33.
2. Bouchard J, Quimet D, Vallee M, Lafrance JP, Leblanc M, Senecal L, Bonnadeaux A, Mathieu JP, Pichette V. Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic population. Int Urol Nephrol 2009; 41:983-8.
3. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in haemododialysis patients. J Ren Nutr 2008;18:395-9.
4. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcome in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 2008;87:1631-83.
5. Cooke NE, Haddad JG. Vitamin D binding protein (Gc-globulin). Endocrinol Rev 1989;10:294-307.
6. Komaba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia 2009;29(5):392-6.
7. Kuro-o M. Klotho and aging. Biochim Biophys 2009;1790(10):1049-58.
8. Zehnder D, Bland R, Williams MC. Extrarenal expression of 25-Hydroxyvitamin D3-1 alpha-Hydroxylase. J Clin Endocrinol Metab 2001;86(2):888-94.
9. Wiese RJ, Uhland-Smith A, Ross TK. Up-regulation of the Vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992;267(28):20082-6.
10. Tian J, Liu Y, Williams LA, De Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007;22(2):321-8.
11. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008;3:1535-41.
12. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:8-28.
13. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007;67(14):1999-2012.
14. Müller K, Haahr PM, Diamant M. 1,25-dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992;4(6):506-12.
15. Dietrich T, Nunn M, Dawson-Hughes B. Association between serum concentrations of 25-hydroxyvitamin D3 and gingival inflammation. Am J Clin Nutr 2005;82(3):575-80.
16. Li YC, Kong J, Wei M. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110(2):229-38.
17. Mehrotra R, Kermah DA, Salusky IB. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009;76(9):977-83.
18. De Boer IH, Ioannou GN, Kestenbaum B. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50(1):69-77.
19. Forman JP, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC. Plasma 25-Hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063-9.
20. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29:650-6.
21. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167(16):1730-7.
22. Repo JM, Rantala IS, Honkanen TT. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007;72(8):977-84.
23. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168(12):1340-9.
24. Wang TJ, Pencina MJ, Booth Sl. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-11.
25. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011;79(7):715-29.
26. Martin KJ, González EA. Vitamin D supplementation in CKD. Clin Nephrol 2011;75:286-93.
27. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-S130.
28. Bhan I, Burnett-Bowie SA, Ye J, Tonelli M, Thadhani R. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 2010;5(3):460-7.
29. ATC/DDD Methodology, WHOCCDS. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD); Actualization 2010. Available at: http://www.whocc.no/atc_ddd_index/?code=H05BX.
30. Torregrosa JV, Bover J, Cannata Andía J, Lorenzo V, De Francisco AL, Martínez I, et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseomineral en los pacientes con enfermedad renal crónica (S.E.N.-M.B.D.). Nefrologia 2011;31(Suppl 1):3-32.
31. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006;129(1):174-81.
32. Kandula P, Dobre M, Schold JD. Vitamin D supplementation in chronic kidnye disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011;6:50-62.
33. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring diálisis. Cochrane Database Sys Rev 2009;CD008175.
34. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring diálisis. Cochrane Database Sys Rev 2009; CD005633.
35. Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodiálisis patients: a randomized crossover trial. Kidney Int 2011; Advance online publication, 10 August 2011. Doi: 10.1038/ki.2011.226
36. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315-23.
37. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews 2011, Issue 7, Art n.° CD007470. DOI: 10.1002/14651858.CD007470.pub2.
38. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamine D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1529-39.
39. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276(14):1172-7.
40. Teng M, Wolf M, Lowrie E. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-9.
41. Dobrez DG, Mathes A, Amdahl M. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004;19:1174-81.
42. Tentori F, Hunt WC, Stidley CA. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70(10):1858-65.
43. Kalantar-Zadeh K, Kuwae N, Regidor DL. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70(4):771-80.
44. Young EW. Vitamin D therapy and mortality in the dialysis outcomes and practice patterns study (DOPPS) J Am Soc Nephrol 2005;16 (abstract).
45. Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, Van Wyck D, Greenland S, et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008;3(6):1769-76.
46. Pharmaceutical Benefits Advisory Committee (PBAC). March 2009. Department of Health and Ageing. Australian Government. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/A4040A375C 280384CA2575D80012EC63/$File/ParicalcitolAbbott PSD 7-6 2009-03 Final.pdf.
47. Nuijten M, Andress DL, Marx SE, Curry AS, Sterz R. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Invest 2010;30(8):545-57.
48. Schumock GT, Arruda J A, Marx SE. Pharmacoeconomic analysis of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis: impact of hospitalisations and survival. J Med Econ 2007;10:393-409.
49. Rosery H, Bergemann R, Marx SE. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Invest 2006;26:629-38.
50. All Wales Medicines Strategy Group Final Appraisal Report Paricalcitol (Zemplar®). August 2009. Available at: http://www.wales.nhs.uk/sites3/Documents/371/paricalcitol(Zemplar)FAR.pd f.
51. Scottish Medicines Consortium (SMC). Drugs not recommended by the SMC, March 2011. Available at:http://www.ljf.scot.nhs.uk/smc_lists/smc_not_recommended_drugs.pdf.